Skip to main content
Caplight Logo









NeuCyte

NeuCyte

Private
Mountain View, CaliforniaHealthcare & Life Scienceshttps://www.neucyte.com/

Last Round

Grant

May 14, 2024

Total Funding Raised

$7.75M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

NeuCyte is a biotechnology company that has developed a target-identification and drug-discovery platform designed to create medicines for the treatment of neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Non-AI

Keywords

iPSC-derived neural cellsCNS drug discoverydisease modelinginduced pluripotent stem cellsiPSCneurotoxicity assessmentin vitro modelsdisease in a dishpreclinical CROcompound screeningcell-based assaysSynFirestem cell modelsassay developmentphenotypic screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuCyte Comparables

Compare NeuCyte with similar companies based on industry and business-model similarity.

NeuCyte comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BrainXell
86%
28bio
86%
Tempo Bioscience, Inc.
84%

NeuCyte Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 14, 2024
GrantAug 14, 2023
Series AMay 8, 2018

NeuCyte Investors

Notable investors and investment history

NeuCyte investors
InvestorRounds
Shenzhen Leaguer Tsing-Yuan Venture Capital ManagementSeries A
Co-Win VenturesSeries A
NIH RADxGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased from 0 to 21, representing 191% of headcount.

  • Jan 25, 2025

    Monthly visitors increased 38% MoM, reaching 2.2K.

NeuCyte Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NeuCyte Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NeuCyte's valuation, stock price, and market status.

Firmographic Details

HeadquartersMountain View, California
Employee Range11
Year Founded2015
Last FundingMay 14, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?